⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22030286 | 0.85 | — | — | |
| SCHEMBL25294952 | 0.73 | — | — | |
| SCHEMBL22305484 | 0.71 | TTR (0.33) | — | |
| SCHEMBL29508605 | 0.71 | — | — | |
| SCHEMBL29069008 | 0.71 | — | — | |
| SCHEMBL29508642 | 0.67 | — | — | |
| SCHEMBL93685 | 0.67 | — | — | |
| SCHEMBL29575479 | 0.65 | — | — | |
| Hydrochloric Acid SCHEMBL9624623 | 0.65 | — | — | |
| SCHEMBL76031 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 241 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3632904-B1 | URAT1 INHIBITORS FOR PROMOTING URIC ACID EXCRETION | JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO LTD (CN) | 2022-04-20 | — | — | EP | claimed |
| US-20200262832-A1 | URAT1 INHIBITOR FOR PROMOTING URIC ACID EXCRETION | JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) | 2020-08-20 | — | — | US | claimed |
| EP-3632904-A1 | URAT1 INHIBITOR FOR PROMOTING URIC ACID EXCRETION | Jiangsu Atom Bioscience And Pharmaceutical Co., Ltd. (CN) | 2020-04-08 | — | — | EP | claimed |
| CN-108484600-A | The URAT1 inhibitor of uricosuric excretion | 江苏新元素医药科技有限公司 | 2018-09-04 | — | — | CN | claimed |
| EP-1542692-B1 | AMINOPYRIMIDINE DERIVATIVES FOR USE AS VANILLOID RECEPTOR LIGANDS FOR THE TREATMENT OF PAIN | AMGEN INC (US) | 2011-01-05 | — | — | EP | claimed |
| EP-2270006-A1 | Pyridazine derivatives useful as vanilloid receptor ligands | Amgen, Inc (US) | 2011-01-05 | — | — | EP | claimed |
| US-7524874-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2009-04-28 | — | — | US | claimed |
| US-7439360-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2008-10-21 | — | — | US | claimed |
| US-7396831-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2008-07-08 | — | — | US | claimed |
| US-7390907-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2008-06-24 | — | — | US | claimed |
| US-20050277631-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2005-12-15 | — | — | US | claimed |
| US-20050277646-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2005-12-15 | — | — | US | claimed |
| US-20050272777-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2005-12-08 | — | — | US | claimed |
| US-20050267163-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2005-12-01 | — | — | US | claimed |
| CN-1694873-A | Vanilloid receptor ligands and their use in treatments | AMGEN INC (US) | 2005-11-09 | — | — | CN | claimed |
| US-20040152690-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2004-08-05 | — | — | US | claimed |
| US-20040082780-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN, INC. | 2004-04-29 | — | — | US | claimed |
| US-20040038969-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN, INC. | 2004-02-26 | — | — | US | claimed |
| US-20030195201-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2003-10-16 | — | — | US | claimed |
| US-6512054-B2 | Reacting polymers having reactive carboxylic acid groups with a methacrylated oxazoline or oxazine; dental restoratives | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION | 2003-01-28 | — | — | US | claimed |